Wang Luyang, Wang Hairui, Yang Chen, Wu Yunyi, Lei Guojie, Yu Yanhua, Gao Yan, Du Jing, Tong Xiangmin, Zhou Feifei, Li Yanchun, Wang Ying
Laboratory Medicine Center, Department of Clinical Laboratory, Zhejiang Provincial People's Hospital (Affiliated People's Hospital, Hangzhou Medical College), Hangzhou, China.
Department of Central Laboratory, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Front Genet. 2022 Jun 17;13:900111. doi: 10.3389/fgene.2022.900111. eCollection 2022.
Breast invasive carcinoma (BRCA) is a carcinoma with a fairly high incidence, and the therapeutic schedules are generally surgery and chemotherapy. However, chemotherapeutic drugs tend to produce serious toxic side effects, which lead to the cessation of treatment. Therefore, it is imperative to develop treatment strategies that are more effective and have fewer side effects at the genetic level. Centromeric protein W () is an oncogene that plays an important part in nucleosome assembly. To date, no studies have reported the prognostic significance of in breast carcinoma. In this study, we verified that expression is up-regulated in breast carcinoma and positively associated with the level of immune cell infiltration. The clinicopathological characteristics further suggest that expression is correlated with a worse prognosis of breast carcinoma. Interestingly, the mutation contributes to the poor prognosis. Next, we discovered that the genes interacting with are mainly concentrated in the cell cycle pathway, and is co-expressed with , which is also highly expressed in breast carcinoma and leads to a worse prognosis. Our subsequent studies verified that knockdown of significantly inhibits the proliferation and migration of breast carcinoma cells and promotes their apoptosis rate. Notably, inhibition of CEMPW sensitizes breast cancer cells to chemotherapeutic drugs that have been found to induce cell cycle arrest. In summary, these results provide extensive data and experimental evidence that can serve as a novel predictor of breast cancer and may act as a prospective therapeutic target.
乳腺浸润性癌（BRCA）是一种发病率较高的癌症，其治疗方案通常为手术和化疗。然而，化疗药物往往会产生严重的毒副作用，导致治疗中断。因此，迫切需要在基因层面开发更有效且副作用更少的治疗策略。着丝粒蛋白W（CEMPW）是一种在核小体组装中起重要作用的癌基因。迄今为止，尚无研究报道CEMPW在乳腺癌中的预后意义。在本研究中，我们证实CEMPW在乳腺癌中表达上调，且与免疫细胞浸润水平呈正相关。临床病理特征进一步表明，CEMPW表达与乳腺癌预后较差相关。有趣的是，CEMPW突变导致预后不良。接下来，我们发现与CEMPW相互作用的基因主要集中在细胞周期途径，且CEMPW与UBE2C共表达，UBE2C在乳腺癌中也高表达并导致预后较差。我们随后的研究证实，敲低CEMPW可显著抑制乳腺癌细胞的增殖和迁移，并提高其凋亡率。值得注意的是，抑制CEMPW可使乳腺癌细胞对已发现能诱导细胞周期停滞的化疗药物敏感。总之，这些结果提供了大量数据和实验证据，表明CEMPW可作为乳腺癌的一种新型预测指标，并可能成为一种有前景的治疗靶点。
